AR039413A1 - Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR039413A1
AR039413A1 ARP030101310A ARP030101310A AR039413A1 AR 039413 A1 AR039413 A1 AR 039413A1 AR P030101310 A ARP030101310 A AR P030101310A AR P030101310 A ARP030101310 A AR P030101310A AR 039413 A1 AR039413 A1 AR 039413A1
Authority
AR
Argentina
Prior art keywords
group
general formula
alkyl
hydrogen atom
alkyl group
Prior art date
Application number
ARP030101310A
Other languages
English (en)
Inventor
Genevieve Estenne-Bouhtou
Pascale Magat
Benoit Marabout
Florence Medaisko
Gihad Dargazanli
Pierre Roger
Mireille Sevrin
Corinne Veronique
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR039413A1 publication Critical patent/AR039413A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: compuesto en forma de isómero óptico puro (1R, 2R) ó (1S, 2S) ó en forma de diastereoisómero treo, caracterizado porque responde a la fórmula general (1): en la cuaL: A representa o bien un grupo de fórmula general N-R1 en la cual R1 representa, o bien un átomo de hidrógeno, o bien un grupo alquilo (C1-7) lineal o ramificado eventualmente sustituido por uno o varios átomos de flúor, o bien un grupo cicloalquilo (C4-7), o bien un grupo cicloalquilo(C3-7)-alquilo(C1-3), o bien un grupo fenilalquilo (C1-3) eventualmente sustituido por uno o dos grupos hidroxi o metoxi, o bien un grupo alquenilo (C2-4), o bien un grupo alquinilo (C2-4), o bien un grupo de fórmula general N+(O-)R1 en la cual R1 es tal como se ha definido anteriormente, o bien un grupo de fórmula general N+(R')R1 en la cual R' representa un grupo alquilo (C1-7) lineal o ramificado y r1 es tal como se ha definido anteriormente; X representa un átomo de hidrógeno o uno o varios sustituyentes elegidos entre los átomos de halógeno y los grupos trifluorometilo, alquilo (C1-4) lineal o ramificada y alcoxi (C1-4); R2 representa o bien un átomo de hidrógeno bien uno o varios sustituyentes elegidos entre los átomos de halógenos y los grupos trifluorometilo, alquilo (C1-4), alcoxi (C1-4), amino de fórmula general NR3R4 en la cual R3 y R4 representan cada uno, independientemente del otro, un átomo de hidrógeno o un grupo alquilo (C1-4), o forman con el átomo de nitrógeno que los lleva, un ciclo pirrolidino piperidino o morfolino, o bien un grupo fenilo eventualmente sustituido por un átomo o un grupo tal como se han definido para el símbolo X anteriormente, en estado de base libre o de sal de adición con un ácido.
ARP030101310A 2002-04-19 2003-04-15 Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica AR039413A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0204916A FR2838739B1 (fr) 2002-04-19 2002-04-19 Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR039413A1 true AR039413A1 (es) 2005-02-16

Family

ID=28686193

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101310A AR039413A1 (es) 2002-04-19 2003-04-15 Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica

Country Status (35)

Country Link
US (2) US7326722B2 (es)
EP (1) EP1499589B1 (es)
JP (1) JP4597532B2 (es)
KR (2) KR101019313B1 (es)
CN (1) CN100482646C (es)
AR (1) AR039413A1 (es)
AT (1) ATE361279T1 (es)
AU (1) AU2003262420B2 (es)
BR (1) BR0309397A (es)
CA (1) CA2481461C (es)
CO (1) CO5631432A2 (es)
CY (1) CY1108025T1 (es)
DE (1) DE60313602T2 (es)
DK (1) DK1499589T3 (es)
EA (1) EA007225B1 (es)
EC (1) ECSP045369A (es)
ES (1) ES2286444T3 (es)
FR (1) FR2838739B1 (es)
HR (1) HRP20040977B1 (es)
IL (2) IL164400A0 (es)
IS (1) IS2540B (es)
MA (1) MA27192A1 (es)
ME (1) MEP25608A (es)
MX (1) MXPA04010326A (es)
NO (1) NO329065B1 (es)
NZ (1) NZ536015A (es)
PL (1) PL373195A1 (es)
PT (1) PT1499589E (es)
RS (1) RS51888B (es)
SI (1) SI1499589T1 (es)
TN (1) TNSN04208A1 (es)
TW (1) TWI306402B (es)
UA (1) UA78025C2 (es)
WO (1) WO2003089411A1 (es)
ZA (1) ZA200408154B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
WO2005044810A1 (en) * 2003-10-30 2005-05-19 Janssen Pharmaceutica, N.V. Glyt2 modulators
CA2609972C (en) 2004-03-22 2013-05-14 Apkarian Technologies Llc Method and compositions for treatment of chronic neuropathic pain
JP4193949B2 (ja) * 2005-04-08 2008-12-10 ファイザー・プロダクツ・インク Ｉ型グリシン輸送阻害剤としての二環式［３．１．０］ヘテロアリールアミド
JP2009179562A (ja) * 2006-08-11 2009-08-13 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
TW200911808A (en) * 2007-07-23 2009-03-16 Astrazeneca Ab Novel compounds
EP2178842A2 (en) 2007-08-22 2010-04-28 Abbott GmbH & Co. KG 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
CN102083797B (zh) 2008-04-01 2014-06-04 Abbvie公司 四氢异喹啉、含有它们的药物组合物和它们在治疗中的用途
WO2010087761A1 (en) * 2009-01-28 2010-08-05 Astrazeneca Ab 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
JP5618047B2 (ja) * 2010-01-29 2014-11-05 国立大学法人千葉大学 ポジトロン断層撮影法およびポジトロン放出化合物
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
MX2013015274A (es) 2011-06-24 2014-03-31 Amgen Inc Anatagonista trpm8 y su uso en tratamientos.
EP2739614B1 (en) 2011-08-05 2017-02-22 AbbVie Deutschland GmbH & Co KG AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY
CN104011028A (zh) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
FR2983197B1 (fr) * 2011-11-29 2014-07-25 Assist Publ Hopitaux De Paris Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3057958B1 (en) 2013-10-17 2019-05-01 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
SG11201602982YA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
FR3045044B1 (fr) * 2015-12-11 2019-04-19 Liphatech Composition et appat rodonticide comprenant du flocoumafene, procede de lutte contre des rongeurs cibles nuisibles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
JP3026845B2 (ja) * 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
US5524569A (en) 1995-03-20 1996-06-11 Rich; William A. Anchor cover
SK13092000A3 (sk) * 1998-03-06 2001-03-12 Janssen Pharmaceutica N. V. Inhibítory prenosu glycínu, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
CA2406652A1 (en) * 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors

Also Published As

Publication number Publication date
ZA200408154B (en) 2005-10-10
SI1499589T1 (sl) 2007-10-31
US7326722B2 (en) 2008-02-05
DE60313602T2 (de) 2008-01-10
MA27192A1 (fr) 2005-01-03
ES2286444T3 (es) 2007-12-01
FR2838739B1 (fr) 2004-05-28
UA78025C2 (en) 2007-02-15
CA2481461C (en) 2010-01-12
CA2481461A1 (en) 2003-10-30
CY1108025T1 (el) 2013-09-04
KR20080075236A (ko) 2008-08-14
TNSN04208A1 (fr) 2007-03-12
CN1662497A (zh) 2005-08-31
HRP20040977A2 (en) 2004-12-31
EA007225B1 (ru) 2006-08-25
TW200306830A (en) 2003-12-01
PL373195A1 (en) 2005-08-22
NO329065B1 (no) 2010-08-09
DK1499589T3 (da) 2007-09-10
WO2003089411A1 (fr) 2003-10-30
JP4597532B2 (ja) 2010-12-15
RS51888B (en) 2012-02-29
AU2003262420B2 (en) 2009-02-19
BR0309397A (pt) 2005-03-01
IL164400A0 (en) 2005-12-18
HRP20040977B1 (en) 2008-04-30
IS7479A (is) 2004-09-30
ECSP045369A (es) 2005-03-10
IS2540B (is) 2009-09-15
AU2003262420A1 (en) 2003-11-03
IL164400A (en) 2010-11-30
KR20040103973A (ko) 2004-12-09
CN100482646C (zh) 2009-04-29
EP1499589B1 (fr) 2007-05-02
EP1499589A1 (fr) 2005-01-26
MEP25608A (en) 2010-06-10
TWI306402B (en) 2009-02-21
EA200401172A1 (ru) 2005-04-28
CO5631432A2 (es) 2006-04-28
US20050159450A1 (en) 2005-07-21
US20070197601A1 (en) 2007-08-23
NO20044388L (no) 2005-01-19
FR2838739A1 (fr) 2003-10-24
ATE361279T1 (de) 2007-05-15
JP2005527593A (ja) 2005-09-15
MXPA04010326A (es) 2005-07-05
PT1499589E (pt) 2007-08-10
RS91404A (en) 2007-02-05
KR101019313B1 (ko) 2011-03-07
DE60313602D1 (de) 2007-06-14
NZ536015A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
AR039413A1 (es) Derivados de n-(fenil(piperidin-2-il)metil)benzamida, su preparacion y su aplicacion en terapeutica
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
AR064730A1 (es) Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
AR064732A1 (es) Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk
AR047823A1 (es) Derivados de 1,2,3,4-tetrahidroisoquinolina sustituida
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
DK1385926T3 (da) Smöreoliesammensætning der omfatter en tilsætningsstofkombination af en carboxylsyre og en amin som antirustmiddel
AR056337A1 (es) Derivados de alquil-, alquenil- y alquinilcarbamatos, su preparacion y su aplicacion en terapeutica
AR052915A1 (es) Derivados de pirrolidin y piperidin acetileno
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR061377A1 (es) Derivados diazeniodiolatos, procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos en patologias cardiovasculares.
AR057464A1 (es) Procedimiento para la preparacion de derivados de sulfonamida
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
UY32801A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR9499A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR069643A1 (es) Derivados diazenidiolatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR054584A1 (es) Inhibidores de la bomba de protones isotopicamente sustituidos
AR047742A1 (es) Compuestos con actividad antitumoral
AR054120A1 (es) Compuestos de fenilpiridilpiperazina, procedimiento de preparacion, composiciones farmaceuticas que los contienen, y usos farmacologicos como antagonistas de receptores histaminergicos h3
CO6321242A2 (es) Compuestos de n-fenil-imidazo[1,2-alfa]piridin-2-carboxamidas su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure